236 related articles for article (PubMed ID: 23300534)
1. Inhibitory effect of tumor suppressor p53 on proinflammatory chemokine expression in ovarian cancer cells by reducing proteasomal degradation of IκB.
Son DS; Kabir SM; Dong YL; Lee E; Adunyah SE
PLoS One; 2012; 7(12):e51116. PubMed ID: 23300534
[TBL] [Abstract][Full Text] [Related]
2. CXCR2-driven ovarian cancer progression involves upregulation of proinflammatory chemokines by potentiating NF-κB activation via EGFR-transactivated Akt signaling.
Dong YL; Kabir SM; Lee ES; Son DS
PLoS One; 2013; 8(12):e83789. PubMed ID: 24376747
[TBL] [Abstract][Full Text] [Related]
3. The deubiquitinating enzyme USP11 controls an IkappaB kinase alpha (IKKalpha)-p53 signaling pathway in response to tumor necrosis factor alpha (TNFalpha).
Yamaguchi T; Kimura J; Miki Y; Yoshida K
J Biol Chem; 2007 Nov; 282(47):33943-8. PubMed ID: 17897950
[TBL] [Abstract][Full Text] [Related]
4. Fn14 overcomes cisplatin resistance of high-grade serous ovarian cancer by promoting Mdm2-mediated p53-R248Q ubiquitination and degradation.
Wu AY; Gu LY; Cang W; Cheng MX; Wang WJ; Di W; Huang L; Qiu LH
J Exp Clin Cancer Res; 2019 Apr; 38(1):176. PubMed ID: 31023317
[TBL] [Abstract][Full Text] [Related]
5. Keratinocyte chemoattractant (KC)/human growth-regulated oncogene (GRO) chemokines and pro-inflammatory chemokine networks in mouse and human ovarian epithelial cancer cells.
Son DS; Parl AK; Rice VM; Khabele D
Cancer Biol Ther; 2007 Aug; 6(8):1302-12. PubMed ID: 17712227
[TBL] [Abstract][Full Text] [Related]
6. Nodakenin suppresses lipopolysaccharide-induced inflammatory responses in macrophage cells by inhibiting tumor necrosis factor receptor-associated factor 6 and nuclear factor-κB pathways and protects mice from lethal endotoxin shock.
Rim HK; Cho W; Sung SH; Lee KT
J Pharmacol Exp Ther; 2012 Sep; 342(3):654-64. PubMed ID: 22637723
[TBL] [Abstract][Full Text] [Related]
7. NF-κB-Mediated CCL20 Reigns Dominantly in CXCR2-Driven Ovarian Cancer Progression.
Ignacio RM; Kabir SM; Lee ES; Adunyah SE; Son DS
PLoS One; 2016; 11(10):e0164189. PubMed ID: 27723802
[TBL] [Abstract][Full Text] [Related]
8. MDM2-Driven Ubiquitination Rapidly Removes p53 from Its Cognate Promoters.
Henningsen KM; Manzini V; Magerhans A; Gerber S; Dobbelstein M
Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053170
[TBL] [Abstract][Full Text] [Related]
9. The crosstalk between ubiquitin-conjugating enzyme E2Q1 and p53 in colorectal cancer: An in vitro analysis.
Rasouli M; Khakshournia S; Vakili O; Dastghaib S; Seghatoleslam A; Shafiee SM
Med Oncol; 2023 Jun; 40(7):199. PubMed ID: 37294480
[TBL] [Abstract][Full Text] [Related]
10. The degradation of p53 and its major E3 ligase Mdm2 is differentially dependent on the proteasomal ubiquitin receptor S5a.
Sparks A; Dayal S; Das J; Robertson P; Menendez S; Saville MK
Oncogene; 2014 Sep; 33(38):4685-96. PubMed ID: 24121268
[TBL] [Abstract][Full Text] [Related]
11. Proteasome inhibition increases recruitment of IκB kinase β (IKKβ), S536P-p65, and transcription factor EGR1 to interleukin-8 (IL-8) promoter, resulting in increased IL-8 production in ovarian cancer cells.
Singha B; Gatla HR; Manna S; Chang TP; Sanacora S; Poltoratsky V; Vancura A; Vancurova I
J Biol Chem; 2014 Jan; 289(5):2687-700. PubMed ID: 24337575
[TBL] [Abstract][Full Text] [Related]
12. Oligomerization conditions Mdm2-mediated efficient p53 polyubiquitylation but not its proteasomal degradation.
Hjerpe R; Aillet F; Lopitz-Otsoa F; Lang V; Torres-Ramos M; Farrás R; Hay RT; Rodríguez MS
Int J Biochem Cell Biol; 2010 May; 42(5):725-35. PubMed ID: 20080206
[TBL] [Abstract][Full Text] [Related]
13. Lipopolysaccharide downregulates the expression of p53 through activation of MDM2 and enhances activation of nuclear factor-kappa B.
Odkhuu E; Mendjargal A; Koide N; Naiki Y; Komatsu T; Yokochi T
Immunobiology; 2015 Jan; 220(1):136-41. PubMed ID: 25172547
[TBL] [Abstract][Full Text] [Related]
14. Crucial role of TSC-22 in preventing the proteasomal degradation of p53 in cervical cancer.
Yoon CH; Rho SB; Kim ST; Kho S; Park J; Jang IS; Woo S; Kim SS; Lee JH; Lee SH
PLoS One; 2012; 7(8):e42006. PubMed ID: 22870275
[TBL] [Abstract][Full Text] [Related]
15. Dynamics in the p53-Mdm2 ubiquitination pathway.
Brooks CL; Gu W
Cell Cycle; 2004 Jul; 3(7):895-9. PubMed ID: 15254415
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional repression of IKKβ by p53 in arsenite-induced GADD45α accumulation and apoptosis.
Hu Y; Jin R; Gao M; Xu H; Zou S; Li X; Xing C; Wang Q; Wang H; Feng J; Hu M; Song L
Oncogene; 2019 Jan; 38(5):731-746. PubMed ID: 30177839
[TBL] [Abstract][Full Text] [Related]
17. The Wip1 Phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop.
Lu X; Ma O; Nguyen TA; Jones SN; Oren M; Donehower LA
Cancer Cell; 2007 Oct; 12(4):342-54. PubMed ID: 17936559
[TBL] [Abstract][Full Text] [Related]
18. Regulation of p53 family member isoform DeltaNp63alpha by the nuclear factor-kappaB targeting kinase IkappaB kinase beta.
Chatterjee A; Chang X; Sen T; Ravi R; Bedi A; Sidransky D
Cancer Res; 2010 Feb; 70(4):1419-29. PubMed ID: 20145131
[TBL] [Abstract][Full Text] [Related]
19. Enhanced heat shock protein 70 expression alters proteasomal degradation of IkappaB kinase in experimental acute respiratory distress syndrome.
Weiss YG; Bromberg Z; Raj N; Raphael J; Goloubinoff P; Ben-Neriah Y; Deutschman CS
Crit Care Med; 2007 Sep; 35(9):2128-38. PubMed ID: 17855826
[TBL] [Abstract][Full Text] [Related]
20. Nuclear factor-kappaB-dependent expression of metastasis suppressor KAI1/CD82 gene in lung cancer cell lines expressing mutant p53.
Shinohara T; Miki T; Nishimura N; Nokihara H; Hamada H; Mukaida N; Sone S
Cancer Res; 2001 Jan; 61(2):673-8. PubMed ID: 11212267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
